MOv18 IgE
MOv18 IgE is an IgE antibody targeting folate receptor alpha (FR alpha), an antigen present on a variety of cancers including ovarian, endometrial, lung and Triple Negative Breast Cancer. MOv18 IgE is the world’s first IgE antibody to enter the clinic and has successfully completed a phase I trial in platinum-resistant ovarian cancer patients. The antibody was found to be safe and well tolerated with initial signs of clinical activity seen.
